Overview

Brimonidine Tartrate for the Treatment of Injection Related Erythema

Status:
Withdrawn
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo). The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin.
Phase:
Phase 4
Details
Lead Sponsor:
Biogen
Treatments:
Brimonidine Tartrate
Interferon beta-1a
Interferon-beta
Interferons